What failure rate are we willing to accept in cell therapy manufacture? Insights from medical device development
Autologous cell therapies hold great promise in the treatment of many cancers but are generally produced using processes and equipment for which there are concerns as to whether they are sufficiently reliable to support scale-out to 1000s of systems. Medical device development holds important lessons for achieving the required reliability for cell therapy automation equipment.
5G NGSO Broadband Failures – What Next for Investors?
After the LeoSat and OneWeb bankruptcies and Intelsat’s Chapter 11 filing, what’s next for satcom investors? Will the 5G IoT opportunity come into sharper focus? Adrian Hillier and Peter Kibutu revisit their triangle of competitive differentiation in the satcom industry.
Biomimetics evolution at the micron scale and beyond
From Velcro to human flight, biomimicry has inspired the development of products and industries. During the 2020s, microfabrication and other bottom-up approaches will likely lead to many more bio-inspired ideas achieving technical and commercial success, says Fred Hussain.
Sustainable innovation: business model and technology must evolve together
Most companies are already setting themselves specific sustainability targets. The question now is how to meet them. Sam Hair and Michael Sequeira show how business model and technology innovation should work in tandem to achieve improved sustainability success.
Special Delivery: can advanced intracellular delivery enable superior cell therapies for solid tumour treatment – and beyond?
Inspired by the promise of CAR-T cell therapy, new technologies to combat the hostile solid tumour microenvironment are being developed, underpinned by innovations in intracellular delivery, say Megan McCandless and Stuart Lowe.
Only a ‘click’ away: click chemistry transforms life science applications
Click chemistry has come into its own in a wide range of life science applications and opens up opportunities that lie between chemistry, biology and material science, says Wenshu Xu.
Accelerating medical device development: Lessons from CoVent and the UK ventilator challenge
Developing a medical device in weeks rather than years during the coronavirus pandemic was an extraordinary undertaking. Dan Strange reviews TTP’s “Project Jarre” to develop the CoVent(TM) ventilator and draws some lessons as to how – when needs must – faster medical device development is possible.
DNA Origami: What can we make of it?
From smiley faces to diagnostic sensors, the possibility of using DNA as a nanofabrication material is gaining increasing attention. Gary Skinner explains “DNA Origami,” its applications and what is holding back its wider adoption into the marketplace.
Key early-stage microfabrication decisions for life science start-ups and SMEs
Many companies face important early-stage decisions about how best to access cleanroom and laboratory facilities, equipment and know-how towards microfabrication – get these decisions wrong and progress to market can become painfully slow, says Fred Hussain.
Spotlight on upconversion nanoparticles: finding the right chemistry to make life science applications “click”
Biomedical imaging and diagnostic platforms increasingly demand stable detection reagents and quantifiable signal output. Upconversion nanoparticles fit the bill and, in the hands of Wenshu Xu and Verity Jackson, allow for multiplex biomarker detection.